Literature DB >> 3608348

The effect of antipyrine and rifampin on the metabolism of diazepam.

E E Ohnhaus, N Brockmeyer, P Dylewicz, H Habicht.   

Abstract

The elimination of diazepam and antipyrine and the urinary excretion of their metabolites were investigated in 21 healthy volunteers before and after 7 days of administration of antipyrine, 1200 mg, and rifampin, 600 or 1200 mg. After administration of antipyrine and rifampin in two doses, antipyrine total body clearance increased by 53% and 60% or 98%, respectively. The clearance to metabolite showed a preferential induction of the norantipyrine pathway with different proportions after antipyrine and rifampin; rifampin, 1200 mg, also enhanced the 4-hydroxyantipyrine pathway further. After antipyrine, diazepam total body clearance was increased by 102%, affecting all metabolic pathways to a similar extent. After rifampin in both doses, diazepam total body clearance rose equally to 300% and desmethyl- and 3-hydroxydiazepam metabolic clearance to 400%. Therefore rifampin preferentially affects norantipyrine or desmethyl- and 3-hydroxydiazepam metabolic formation, suggesting induction of different (iso)zymes of cytochrome P-450.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3608348     DOI: 10.1038/clpt.1987.125

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  12 in total

1.  Evaluation of human liver slices and reporter gene assays as systems for predicting the cytochrome p450 induction potential of drugs in vivo in humans.

Authors:  Kajsa P Persson; Susanne Ekehed; Charlotta Otter; E S Mareike Lutz; Jane McPheat; Collen M Masimirembwa; Tommy B Andersson
Journal:  Pharm Res       Date:  2006-11-22       Impact factor: 4.200

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 3.  Clinically significant interactions with drugs used in the treatment of tuberculosis.

Authors:  W W Yew
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

4.  Antipyrine metabolism is not affected by terbinafine, a new antifungal agent.

Authors:  R Seyffer; M Eichelbaum; J C Jensen; U Klotz
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

5.  Pharmacokinetic interaction of antimicrobial agents with levomethadon in drug-addicted AIDS patients.

Authors:  N H Brockmeyer; L Mertins; M Goos
Journal:  Klin Wochenschr       Date:  1991-01-04

Review 6.  Clinical significance of the cytochrome P450 2C19 genetic polymorphism.

Authors:  Zeruesenay Desta; Xiaojiong Zhao; Jae-Gook Shin; David A Flockhart
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 7.  Pharmacokinetic interactions with rifampicin : clinical relevance.

Authors:  Mikko Niemi; Janne T Backman; Martin F Fromm; Pertti J Neuvonen; Kari T Kivistö
Journal:  Clin Pharmacokinet       Date:  2003       Impact factor: 6.447

8.  Two- and four-day rifampin chemoprophylaxis regimens induce oxidative metabolism.

Authors:  S M Borcherding; T L Bastian; T H Self; N Abou-Shala; B W LeDuc; R L Lalonde
Journal:  Antimicrob Agents Chemother       Date:  1992-07       Impact factor: 5.191

Review 9.  Clinically important drug interactions with zopiclone, zolpidem and zaleplon.

Authors:  Leah M Hesse; Lisa L von Moltke; David J Greenblatt
Journal:  CNS Drugs       Date:  2003       Impact factor: 5.749

Review 10.  Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.

Authors:  M M Galteau; F Shamsa
Journal:  Eur J Clin Pharmacol       Date:  2003-11-06       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.